Home › Prostaatkanker › Illinois › Chicago
Prostaatkanker klinische studies in Chicago, IL
45 studies voor Prostaatkanker zoeken deelnemers op locaties in en rond Chicago (binnen ongeveer 30 mijl). Open een studie om te zien wie er kan deelnemen en hoe je contact opneemt met het studieteam.
Officiële studietekst (Engels)
Rekruteren voor een studie? Laat deze bovenaan deze pagina verschijnen — $99 voor 30 dagen →
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
RekruterenFase 3
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
RekruterenFase 3
- Northwestern University, Chicago
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
RekruterenFase 1
- University of Chicago Hospital, Chicago
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Mount Sinai Hospital Medical Center, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- en nog 1
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RekruterenFase 2
- University of Illinois Cancer Center, Chicago
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruterenFase 2
- Rush MD Anderson Cancer Center, Chicago
- University of Chicago Comprehensive Cancer Center, Chicago
Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
RekruterenFase 2/3
- University of Chicago, Chicago
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
RekruterenFase 3
- University of Illinois Chicago, Chicago
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
RekruterenFase 3
- Northwestern University, Chicago
- University of Illinois Cancer Center at Chicago, Chicago
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
RekruterenFase 3
- Research Site, Chicago
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
RekruterenFase 3
- Rush University Medical Center-Hematology and Oncology ( Site 0028), Chicago
- University of Illinois at Chicago-University of Illinois Cancer Center ( Site 0063), Chicago
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RekruterenFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
RekruterenFase 1
- University of Illinois Hospital & Health Sciences System, Chicago
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Rekruteren
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
RekruterenFase 2
- University of Chicago Comprehensive Cancer Center, Chicago
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
RekruterenFase 2
- Jesse Brown VA Medical Center, Chicago, IL, Chicago
A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
RekruterenFase 1/2
- University of Chicago, Chicago
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
RekruterenFase 3
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
- University of Illinois, Chicago
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RekruterenFase 1
- University of Chicago Medical Center, Chicago
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RekruterenFase 1/2
- Research Site, Chicago
PSMA PET Combined With MRI for the Detection of PCa
RekruterenFase 3Gezonde vrijwilligers welkom
- UroPartners,LLC, Chicago
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RekruterenFase 3
- Rush MD Anderson, Chicago
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
RekruterenFase 3
- University of Illinois, Chicago
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
RekruterenFase 2
- Northwestern University, Chicago
rhPSMA-73 PET-MRI Imaging for the Detection of Prostate Cancer Among Men Who Are Otherwise Candidates for Active Surveillance
RekruterenVroege fase 1Gezonde vrijwilligers welkom
- Northwestern University, Chicago
Prostate Cancer Treatment Using Androgen Deprivation Therapy and Focal Prostate Ablation
RekruterenFase 2
- UChicago Medicine Comprehensive Cancer Center, Chicago
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
RekruterenObservatieonderzoek
- University of Illinois at Chicago, Chicago
- Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
- University of Chicago, Chicago
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
RekruterenObservatieonderzoekGezonde vrijwilligers welkom
- Northwestern, Chicago
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
RekruterenFase 1
- Research Site, Chicago
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
RekruterenFase 1/2
- Rush University, Chicago
Clinical Trial of Approaches to Prostate Cancer Surgery
Rekruteren
- Northwestern University, Chicago
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
RekruterenFase 2
- Northwestern University, Chicago
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekruterenFase 1/2
- University of Chicago Medical Center, Chicago
Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
Rekruteren
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
GU-01: Glycyrrhizin in Prostate Cancer
RekruterenFase 2
- University of Illinois, Chicago
PSMA PET for Surveillance After Focal Therapy
Rekruteren
- University of Chicago Medicine Comprehensive Cancer Center, Chicago
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RekruterenFase 1
- The University of Chicago Comprehensive Cancer Center, Chicago
Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)
RekruterenObservatieonderzoek
- The University of Chicago, Hyde Park · 5 mijl verwijderd
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body
RekruterenFase 3
- Northwestern University, Chicago
- University of Illinois, Chicago
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RekruterenFase 4
- University of Chicago Medical Center, Chicago
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruterenObservatieonderzoek
- Massive Bio SYNERGY-AI site, Chicago
Study to Assess the Feasibility of Stopping Prostate Cancer Treatment Early in Elderly Patients
Rekruteren
- The University of Illinois at Chicago (UIC), Chicago
- UChicago Medicine Comprehensive Cancer Center, Chicago
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RekruterenFase 3
- Rush University Medical Center, Chicago
- University of Illinois, Chicago
Geriatric Assessment and Technology Evaluation in Prostate Cancer
RekruterenObservatieonderzoek
- o University of Chicago Medicine Comprehensive Cancer Center, Chicago
Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
RekruterenFase 4
- University of Chicago Medical Center, Chicago
Prostaatkanker studies in andere steden
- New York City, NY103 studies
- Houston, TX76 studies
- Los Angeles, CA61 studies
- Boston, MA59 studies
- St. Louis, MO46 studies
- San Francisco, CA45 studies
- Philadelphia, PA44 studies
- Baltimore, MD43 studies
- Nashville, TN42 studies
- Seattle, WA42 studies
- Washington, DC38 studies
- Dallas, TX36 studies
Andere studies in Chicago
- Niet-kleincellige longkanker61 studies
- Borstkanker58 studies
- Kanker (alle vormen)51 studies
- Metastatische kanker45 studies
- Obesitas41 studies
- Longkanker41 studies
- Eierstokkanker36 studies
- Beroerte34 studies
- Colorectale kanker33 studies
- Hartfalen31 studies
- Overgewicht28 studies
- Plaveiselcelcarcinoom van hoofd en hals26 studies
Van ClinicalTrials.gov, gegevens opgehaald op 5 okt. 2026. Elke studie stelt eigen deelnamecriteria vast; het studieteam bepaalt wie er kan deelnemen.